How to buy Ocular Therapeutix stock | $14.56

Ocular Therapeutix, Inc is a biotechnology business based in the US. Ocular Therapeutix shares (OCUL) are listed on the NASDAQ and all prices are listed in US Dollars. Ocular Therapeutix employs 181 staff and has a trailing 12-month revenue of around 0.00.

Ocular Therapeutix stock price (NASDAQ: OCUL)

Use our graph to track the performance of OCUL stocks over time.

Ocular Therapeutix shares at a glance

• Key figures

Information last updated 2021-07-23.

Latest market close	$14.56
52-week range	$7.14 - $24.30
50-day moving average	$13.70
200-day moving average	$16.77
Wall St. target price	$25.33
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.79

Buy Ocular Therapeutix shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Ocular Therapeutix stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Ocular Therapeutix, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Ocular Therapeutix price performance over time

Historical closes compared with the close of $14.56 from 2021-05-28

1 week (2021-07-18)	N/A
1 month (2021-06-29)	5.81%
3 months (2021-04-29)	-24.01%
6 months (2021-01-25)	N/A

1 year (2020-07-25)	N/A
2 years (2019-07-25)	N/A
3 years (2018-07-25)	N/A
5 years (2016-07-25)	N/A

Ocular Therapeutix financials

Revenue TTM	$22.1 million
Gross profit TTM	$-13,374,000
Return on assets TTM	-26.3%
Return on equity TTM	-360.15%
Profit margin	0%
Book value	$1.09
Market capitalisation	$924.7 million

TTM: trailing 12 months

Shorting Ocular Therapeutix shares

There are currently 5.8 million Ocular Therapeutix shares held short by investors – that's known as Ocular Therapeutix's "short interest". This figure is 10% down from 6.5 million last month.

There are a few different ways that this level of interest in shorting Ocular Therapeutix shares can be evaluated.

Ocular Therapeutix's "short interest ratio" (SIR)

Ocular Therapeutix's "short interest ratio" (SIR) is the quantity of Ocular Therapeutix shares currently shorted divided by the average quantity of Ocular Therapeutix shares traded daily (recently around 813597.33893557). Ocular Therapeutix's SIR currently stands at 7.14. In other words for every 100,000 Ocular Therapeutix shares traded daily on the market, roughly 7140 shares are currently held short.

However Ocular Therapeutix's short interest can also be evaluated against the total number of Ocular Therapeutix shares, or, against the total number of tradable Ocular Therapeutix shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ocular Therapeutix's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Ocular Therapeutix shares in existence, roughly 80 shares are currently held short) or 0.0869% of the tradable shares (for every 100,000 tradable Ocular Therapeutix shares, roughly 87 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Ocular Therapeutix.

Find out more about how you can short Ocular Therapeutix stock.

Ocular Therapeutix share dividends

We're not expecting Ocular Therapeutix to pay a dividend over the next 12 months.

Ocular Therapeutix share price volatility

Over the last 12 months, Ocular Therapeutix's shares have ranged in value from as little as $7.14 up to $24.3. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ocular Therapeutix's is 2.0598. This would suggest that Ocular Therapeutix's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Ocular Therapeutix overview

Ocular Therapeutix, Inc. , a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant administered by the fine-gauge needle that is in phase 1 clinical trial for the treatment of wet age-related macular degeneration; OTX-TIC, a travoprost intracameral implant, which is in phase 1 clinical trial for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that is in phase 2 clinical trial for the chronic treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trial for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company is involved in the development of OTX-AFS, an aflibercept suprachoroidal injection for the treatment of retinal diseases. It has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of Dry Age-related Macular Degeneration.

Frequently asked questions

What percentage of Ocular Therapeutix is owned by insiders or institutions?
Currently 0.463% of Ocular Therapeutix shares are held by insiders and 63.668% by institutions. How many people work for Ocular Therapeutix?
Latest data suggests 181 work at Ocular Therapeutix. When does the fiscal year end for Ocular Therapeutix?
Ocular Therapeutix's fiscal year ends in December. Where is Ocular Therapeutix based?
Ocular Therapeutix's address is: 24 Crosby Drive, Bedford, MA, United States, 01730 What is Ocular Therapeutix's ISIN number?
Ocular Therapeutix's international securities identification number is: US67576A1007 What is Ocular Therapeutix's CUSIP number?
Ocular Therapeutix's Committee on Uniform Securities Identification Procedures number is: 67576A100